Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
Event:
ESC Congress 2017
Topic:
Atrial fibrillation (AF)
Session:
Bleeding and LAA occlusion
